Phase 4 N=21 Treatment of Acute Hepatitis C Virus in HIV Co-Infection
Hepatitis C · Human Immunodeficiency Virus · HIV Infections
Primary: Sustained Virologic Response (SVR) — 62 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=25 HCV Positive Heart Donors
Heart Failure
Primary: Sustained Virologic Response After Treatment — 24 Participants
N/A N=366 Undiagnosed Hepatitis C Infection in an Urban Hospital
Hepatitis C
Primary: Point Prevalence of Hepatitis C Infection — 9 percentage of total subjects
Phase 4 N=15 Hepatitis C Virus(HCV) Heart and Lung Study
Hepatitis C, Chronic · Heart Failure · Pulmonary Disease, Chronic Obstructive
Primary: Number of Subjects Who Completed 24 Weeks of Therapy — 0; 1 Participants
Phase 4 N=18 HCV-HIV Co-infected Patient Cohort in Thailand
Hepatitis C Infection · HIV
Primary: Number of Participants With Sustained Virological Response 6 Months After Treatment Discontinuation — 10 Participants
Phase 1 N=5 Viral Kinetics in HCV Clearance in Subjects With Hemophilia
Chronic Hepatitis C · Hemophilia
Primary: Number of Participants With Sustained Virological Response at Week 12 (SVR12) — 2; 2 participants
Phase 3 N=286 Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)
Hepatitis C Virus (HCV)
Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in the Intention-to-Treat (ITT) Population — 96.2 percentage of…
N/A N=795 Association of Hepatitis C Virus With Breast Cancer
Breast Cancer · Hepatitis C
Primary: Prevalence of HCV Seropositivity in Breast Cancer Patients. — 88; 15; 317; 130 Participants — p=0.0027
N/A N=309 Hepatitis C Translating Initiatives for Depression Into Effective Solutions
Hepatitis C · Depression
Primary: Number of Patients Who Initiated Hepatitis C Antiviral Treatment Within 12 Months of Enrollment — 11; 7 participants
N/A N=68 Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection
HIV · Hepatitis C, Chronic
Primary: Number of Participants Linked to Care — 8; 16 Participants — p=0.036
Phase 2 N=15 Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)
Hepatitis C
Primary: Intrahepatic and Plasma HCV Viral Kinetics — 6.5; 4.9; 3.2; 4.2 log transformed copies/ml
Phase 1 N=44 Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection
HIV-1 Infection · Hepatitis
Primary: Percentage of Participants With Sustained Virologic Response 12 (SVR12) — 58.8; 100.0 Percentage of participants
Phase 2 N=273 Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection
Chronic Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 92.9; 96.2; 74.1; 100.0 percentage of participants
N/A N=21 Hepatitis C Virus (HCV) Treatment Completion or Withdrawal
Hepatitis C
Primary: Attributes of Treatment Experience — 14; 15; 7; 9 participants
Phase 4 N=122 Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant
Hepatitis C · Transplantation Disease Transmission
Primary: Proportion of Participants With HCV RNA Level Below Limits of Quantification (LOQ) — 23 Participants
Phase 2 N=548 Staged Phase I/II Hepatitis C Prophylactic Vaccine
Hepatitis C
Primary: Number of Participants With Chronic Hepatitis C Virus (HCV) Infection at 6 Months — 14; 14 Participants — p=0.317
Phase 2 N=29 Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients
Hepatitis C · HIV Infections
Primary: Number of Participants With Sustained Virologic Response (SVR) — 11; 11 participants
N/A N=529 The Impact on Linkage-to-care of an Alternative Hepatitis C Screening Method in PWID
Hepatitis C · Drug Users · Harm Reduction
Primary: Percentage of HCV Infected Paticipants Whom Result of the Test Was Delivered to — 101 Participants
Phase 2 N=67 Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
HIV Infection · Hepatitis C Infection
Primary: Percentage of Participants With Complete Early Virologic Response (cEVR) — 38.8 percentage of participants
N/A N=134 Hepatitis C Self-Management
Hepatitis C · Chronic Disease
Primary: Quality of Well-being Scale - Self-Administered (QWB-SA) — .534; .501; .600; .504 units on a scale
Phase 2 N=10 Autologous Dendritic Cell Vaccine for Treatment of Patients With Chronic HCV-Infection
Hepatitis C, Chronic · Liver Diseases · Hepatitis
Primary: Number of Participants With Severe Adverse Reactions and/or With Abnormal Clinical Laboratory Values That Are Related to Treatment — 0 Participants
Phase 1 N=20 Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.
Hepatitis, Chronic · Hepatitis C Virus
Primary: Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Day 11 (Cohort A): Full Analysis Set — 6.11; -0.45 log10 IU/mL
Phase 2 N=36 Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients
Hepatitis C · HIV Infections
Primary: Participants With Viral Decline at Day 3 & 28 With Predictors of Post Treatment Response — 8 participants with post treatment svr
Phase 2 N=30 Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV
HIV-HCV
Primary: The Percentage of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 90; 80 Percentage of subjects
Phase 2 N=44 Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients
Hepatitis C Virus Infection
Primary: Mean Log Change in Viral Load From Baseline (Day 1) to Day 28 — 0.30; 0.00; 0.18; 0.04 copies/mL on log scale
Phase 4 N=87 Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
Cardiovascular Diseases · Hepatitis C · Hiv
Primary: Change in Cardiovascular Disease Risk From Baseline to After Functional Cure of Hepatitis C, as Measured by High-sensitivity C-reactive Protein — 0.6; 0 mg/L
Phase 4 N=600 Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia
HCV HIV
Primary: Number of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 516 Participants
Phase 2 N=128 A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study
Hepatitis C
Primary: Comparison of Sustained Viral Response at 12 Weeks Post Treatment (SVR12) in the Three Treatment Groups. — 3; 5; 3; 30 Participants — p=0.67
Phase 4 N=34 Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs
Hepatitis C
Primary: sCD14 (ng/mL) — 1986; 1918; 1542; 2060 ng/mL — p=0.07
Phase 4 N=30 Multi-center Study to Transplant Hepatitis-C Infected Kidneys
Renal Failure Chronic · Hepatitis C
Primary: Number of Participants With Undetectable HCV — 30 Participants